<DOC>
	<DOCNO>NCT00807170</DOCNO>
	<brief_summary>A clinical study investigate maximum tolerate dose Vandetanib concurrent WBRT patient NSCLC brain metastasis . All patient receive WBRT , 10 fraction 3 Gy . Patients start 7 day prior start radiation treatment Vandetanib . Total treatment time Vandetanib 3 week ( 21 day ) . Patients opportunity continue Vandetanib progression dose 300 mg . This multi-centre study conduct minimum 9 patient maximum 18 patient 3 site .</brief_summary>
	<brief_title>Investigate Maximum Tolerated Dose Vandetanib Concurrent Whole Brain Radiotherapy ( WBRT ) Patients With Non-small Cell Lung Cancer ( NSCLC ) Brain Metastases</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Male female patient age 18 year histologically cytologically confirm NSCLC contrastenhanced CT scan Gadoliniumenhanced MRI confirm brain metastasis performance status 0 2 No previous radiotherapy , surgery chemotherapy brain metastases Patients unstable systemic disease Serious abnormal laboratory value Evidence severe uncontrolled systemic disease concurrent condition Investigator 's opinion make undesirable patient participate trial would jeopardize compliance protocol Clinically significant cardiovascular event ( e.g . myocardial infarction , superior vena cava syndrome ( SVC ) , New York Heart Association ( NYHA ) classification heart disease &gt; 2 within 3 month entry ; presence cardiac disease , Previous randomization treatment present study and/ current participation another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Non-small Cell Lung Cancer ( NSCLC )</keyword>
	<keyword>Whole Brain Radiotherapy</keyword>
	<keyword>metastasis</keyword>
</DOC>